Eupraxia Pharmaceuticals Inc. (EPRX) stock

EPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 13, 2026Score 5/30

$8.15+0.34 (+4.35%)

Close on Nov 13, 2026Market cap $491.40MP/E –Yield –

Eupraxia Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $21.33M, up 32.7% from the year before.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$21.33M	+32.7%
FY2024	Dec 31, 2024	$16.08M	-21.0%
FY2023	Dec 31, 2023	$20.36M	+49.4%
FY2022	Dec 31, 2022	$13.63M	–

Parsed from the XBRL in Eupraxia Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EPRX.

Advertisement
300 × 250

See a number that looks wrong?